Cargando…

Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome

Teduglutide is a recombinant analog of human glucagon‐like peptide‐2 that regulates the functional and structural integrity of the cells lining the gastrointestinal tract. Teduglutide is approved for the treatment of patients with short bowel syndrome (SBS) who are dependent on parenteral support (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marier, Jean‐Francois, Jomphe, Claudia, Peyret, Thomas, Wang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604237/ https://www.ncbi.nlm.nih.gov/pubmed/34402197 http://dx.doi.org/10.1111/cts.13117

Ejemplares similares

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Teduglutide for short bowel syndrome
Publicado: (2020)

Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure
por: Fifi, Amanda, et al.
Publicado: (2023)

Emerging treatment options for short bowel syndrome: potential role of teduglutide
por: Tee, Cheng T, et al.
Publicado: (2011)

Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block
por: Vipperla, Kishore, et al.
Publicado: (2014)

Short Bowel Syndrome and Kidney Transplantation: Challenges, Outcomes, and the Use of Teduglutide
por: Abou Diwan, Elizabeth, et al.
Publicado: (2020)

Teduglutide in short bowel syndrome patients: A way back to normal life?
por: Harpain, Felix, et al.
Publicado: (2021)

Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension
por: Nakamura, Shiro, et al.
Publicado: (2022)

Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome
por: Schwartz, Lauren K, et al.
Publicado: (2016)

Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure
por: Chen, Kristina, et al.
Publicado: (2019)

Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support
por: Chiba, Masahiro, et al.
Publicado: (2023)

Gastric Foveolar Hyperplastic Polyps in 2 Children With Short Bowel Syndrome on Long-Term Teduglutide
por: Salazar, Jonathan A., et al.
Publicado: (2023)

Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials
por: Seidner, Douglas L., et al.
Publicado: (2019)

Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome
por: Büttner, Janine, et al.
Publicado: (2023)

Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III Study
por: Kocoshis, Samuel A., et al.
Publicado: (2019)

Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency
por: Reiner, Johannes, et al.
Publicado: (2020)

Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis
por: Bioletto, Fabio, et al.
Publicado: (2022)

Improvement in metabolic indices including thyroid hormones via enhanced absorption of nutrients by Teduglutide in short bowel syndrome
por: Oba, Ken C., et al.
Publicado: (2022)

Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials
por: Pape, Ulrich-Frank, et al.
Publicado: (2020)

Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
por: Wang, Qi, et al.
Publicado: (2018)

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
por: Jeppesen, P B, et al.
Publicado: (2011)

Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes
por: de Dreuille, Brune, et al.
Publicado: (2023)

Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide
por: Fujioka, Ken, et al.
Publicado: (2016)

Safety Findings in Pediatric Patients During Long‐Term Treatment With Teduglutide for Short‐Bowel Syndrome–Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies
por: Hill, Susan, et al.
Publicado: (2021)

Efficacy of teduglutide in a patient with Crohn’s disease and short bowel syndrome on enteral nutrition: let’s start to think out of the box
por: Barberio, Brigida, et al.
Publicado: (2019)

SAT-LB86 Improvement In Metabolic Indices Including Thyroid HormonesVia Enhanced Absorption Of Nutrients By Teduglutide In Short Bowel Syndrome
por: Oba, Ken C, et al.
Publicado: (2020)

Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure—A Nested Matched Pair Real-World Study
por: Blüthner, Elisabeth, et al.
Publicado: (2023)

Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome
por: Iyer, Kishore R., et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Teduglutide in amyloidosis‐associated intestinal failure
por: Luhn, Clara, et al.
Publicado: (2023)

Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials
por: Seidner, Douglas L, et al.
Publicado: (2015)

Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide—9 Years of Follow-Up
por: Zaczek, Zuzanna, et al.
Publicado: (2022)

Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome
por: Chen, Kristina S, et al.
Publicado: (2018)

Case Report: Morphologic and Functional Characteristics of Intestinal Mucosa in a Child With Short Bowel Syndrome After Treatment With Teduglutide: Evidence in Favor of GLP-2 Analog Safety
por: Falco, Enrico Costantino, et al.
Publicado: (2022)

Bridging intestinal failure with Teduglutide – A case report
por: Schlager, Lukas, et al.
Publicado: (2021)

1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients
por: Liu, Jiajun, et al.
Publicado: (2019)

Dose‐dependent elevation in amylase and lipase in response to teduglutide administration
por: Lee, Joshua, et al.
Publicado: (2019)

Use of Teduglutide in Children With Intestinal Failure: A Systematic Review
por: Gigola, Francesca, et al.
Publicado: (2022)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
por: Edwards, JE, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0gdrj3tioinbljlp94tjri1bbf